Young E. Whang
Affiliations: | Pathology | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Pathology, Microbiology BiologyGoogle:
"Young Whang"Children
Sign in to add trainee| Mehmet Karaca | grad student | 2010 | UNC Chapel Hill |
| Dinuka M. De Silva | grad student | 2014 | UNC Chapel Hill |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lam B, Rodgers JE, Muluneh B, et al. (2024) Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer. The Annals of Pharmacotherapy. 10600280231223213 |
| Hanson ED, Alzer M, Carver J, et al. (2022) Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases |
| Kim SI, Szeto AH, Morgan KP, et al. (2021) Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Plos One. 16: e0262326 |
| Kim SI, Szeto AH, Morgan KP, et al. (2021) A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Plos One. 16: e0253021 |
| Xu C, Tsai YH, Galbo PM, et al. (2021) Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. Nucleic Acids Research |
| Hanson ED, Stopforth CK, Alzer M, et al. (2021) Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. Prostate Cancer and Prostatic Diseases |
| Subudhi SK, Siddiqui BA, Maly JJ, et al. (2021) Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 39: TPS5088-TPS5088 |
| Batra JS, Niaz MJ, Whang YE, et al. (2020) Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer. Urologic Oncology |
| Shore ND, Morrow MP, McMullan T, et al. (2020) CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Stopforth CK, Alzer M, Carver J, et al. (2020) BODY COMPOSITION, PHYSICAL FUNCTION AND QUALITY OF LIFE ACROSS DIFFERENT STAGES OF PROSTATE CANCER: A CROSS-SECTIONAL ANALYSIS: 3534 Board #355 May 29 2:30 PM - 4:00 PM Medicine and Science in Sports and Exercise. 52: 981-981 |